pubmed.ncbi.nlm.nih.gov › 36971864

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. 2 Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. glen.wunderlich@ boehringer- ingelheim.com. PMID: 36971864 DOI: 10.1007/s00406-023-01576-z…

pro.boehringer-ingelheim.com › events › cns-congresses › epa-symposium

European Psychiatric Association 2022 Explore Boehringer Ingelheim’s approach to mental health and engage with the symposia on the PRISM project and cognition in schizophrenia convened as part of the European…

link.springer.com › chapter › 10.1007 › 7854_2022_382

Boehringer Ingelheim’s CONNEX Phase III clinical trial program is currently recruiting participants to assess the safety and efficacy of BI 425809 for improving cognition in adults with schizophrenia. The program…

clinicaltrials.gov › ct2 › show › NCT03859973

Boehringer Ingelheim: ClinicalTrials.gov Identifier: NCT03859973 Other Study ID Numbers: 1346-0038 2018-002740-82 ( EudraCT Number ) First Posted: March 1, 2019 Key Record Dates: Last Update Posted: April 25, 2023 Last…

careers.boehringer-ingelheim.com › biberach ›

Cognitive impairment associated with schizophrenia (CIAS) is a major burden for patients and negatively impacts many aspects of a patient's life. Antipsychotics are the standard-of-care treatment for schizophrenia but only…

pro.boehringer-ingelheim.com › ... › epa-symposium-2023 › improving-cognition-video

Improving Cognition Video. Improving Cognition Video cns congress bi. bi. Boehringer Ingelheim Mental Health Back Boehringer Ingelheim Mental Health; Our Commitment Our Pipeline SIRS Back SIRS; BI Mental Health Symposium…

link.springer.com › article › 10.1007 › s00406-023-01576-z

Antipsychotics are the standard-of-care treatment for schizophrenia but only address positive symptoms. So far there are no approved pharmacotherapies for the treatment of CIAS. Iclepertin (BI 425809) is a novel,…

1. NOV. 2021

testgws.bi-hubnext.com › human-health › mental-disorders › schizophrenia

At Boehringer Ingelheim we are driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company we plan in generations. We work…

nature.com › articles › d43747-021-00069-z

The goal is to transform the lives of patients with agents that are truly innovative. Boehringer Ingelheim strives to achieve that goal by seeking out approaches that have the potential…

annualreport.boehringer-ingelheim.com › 2021 › magazine › mental-health-diseases

Researchers at Boehringer Ingelheim have already discovered nine new drugs for psychiatric indications based on this approach, some of which now have the preclinical development phase in their rear view…

pubmed.ncbi.nlm.nih.gov › 33610228

11 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. PMID: 33610228 DOI: 10.1016/S2215-0366(20)30513-7 Abstract Background: Cognitive impairment associated with schizophrenia predicts poor functional outcomes, but currently no approved pharmacotherapy is…

15. SEPT. 2020

clinicaltrialsarena.com › news › boehringer-schizophrenia-data

Boehringer Ingelheim has announced that BI 425809 has improved cognition in stable adults with schizophrenia in a Phase II clinical trial. Results showed that the Gly-T1 inhibitor met its primary…

pubmed.ncbi.nlm.nih.gov › 29718385

10 Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan. PMID: 29718385 ... The key secondary endpoint was change from baseline in Schizophrenia Cognition Rating Scale (SCoRS) total score. Safety was monitored. Results:…

14. SEPT. 2020

fiercebiotech.com › biotech › boehringer-s-schizophrenia-med-boosts-cognition

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or s